Genscript Biotech (HK:1548) has released an update. Genscript Biotech’s subsidiary, Probio Nanjing, has entered into a significant license agreement with LaNova Medicines, granting exclusive rights to ...

GenScript ProBio is the subsidiary of GenScript Biotech Corp. (HK.1548), building upon GenScript’s solid gene synthesis technology and deep expertise in the antibody, cell, and gene therapy fields, ...

PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...

Good day, and thank you for standing by. Welcome to GenScript Biotech Interim Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual ...

PISCATAWAY, N.J. & NEW YORK--(BUSINESS WIRE)--GenScript ProBio, a global contract development and manufacturing organization, and Comprehensive Cell Solutions (CCS), a leader in cell therapy ...

Earnings call GenScript's 2025 revenue surged 61.4% YoY to $959.5M, with adjusted net profit up 285% to $230.3M, fueled by strong segment performance and a major licensing deal. Despite a non-cash ...

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...